Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Our presentation at #AACR24 today - well received with many intriguing conversations.
Grateful and humbled by our lead author Prof @udai_banerji who did not stop speaking for 3.5 hours. Udai - much appreciated
#PeptidesCreateHope
#LetsDoThis
Cancer medications granted accelerated approval are often confirmed despite not demonstrating a benefit in overall survival or quality of life.
In a separate analysis, researchers looked at the reasons why drugs granted accelerated approval between 2013 and 2023 were converted to regular approval. They found that 40% were based on how long people survived, the gold standard for cancer medicines. Another 44% were based on how long people went without their cancer growing; 10% were based on finding that tumors shrank, called response rate, and the duration of that response; and 4% were based on response rate alone. One drug received regular approval despite a confirmatory trial that found no difference in overall survival or time to cancer recurrence between patients receiving the new treatment and those getting the existing standard of care.
Reading this with data Avacta has stated it’s hard not to see AVA6000 approved…..
https://www.cancertodaymag.org/cancer-talk/results-that-matter/?utm_medium=twitter&utm_source=social&sf187596192=1
Gardener working on his abacus now with his Dick Turpin mask on working out how many more free shares he should award to himself and Smith.
Avacta present their poster on day 5 of the AACR Conference.
Simon Bennett Chief Business Officer will have had 4 full days of meetings with BP before the poster,could we get a LD announced next week…
Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
RNS. 5 April 2023
Avacta Group plc
("Avacta" and, together with its subsidiary undertakings, the "Group")
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
All patients still on drug
RAH twitter
That’s 12 months on drug….WOW
Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
How many meetings has Simon scheduled
Sadly just a rehash of December data as I expected but not what I hoped for. Oh well roll on the webinar.
Touk you are a P. Rick
AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent).
No grade 4 non-hematologic toxicities were reported.
That’s should be enough for approval.
Everyone just ignore and report the trolls.
Right all the news we have had about the trial the one piece of news that turned my head was :
Nurses couldn’t tell if patients had been dosed with Chemo
Let that sink in:
These nurses are seeing cancer patients daily watching them deteriorate physically and mentally watching cancer & chemo slowly killing them.
Yet with Ava6000 they couldn’t tell if they were on chemo:
Roll on the 9th & 10th (Holy Grail) results
B2H
I’m not asking for price sensitive info
Just Communication.
Need to start boosting why sit in radio silence keeping investors guessing with SP trashed and Trolls and city shorters in control.
Avacta has Major news on its AVA6000 P1 trial results in a weeks time.
Where is the Communication department are they in the same Bunker as Smith & Gardiner.
Why throw all eggs at one Investor presentation where SP reaction could go 50/50
Start communicating with Media Let CC’s R&D department start to release more clips.
Come on Avacta get a grip start to repair LTH’s trust.
To deliver first-in-class cancer therapies that boost efficacy and minimise off target toxicity.
So not just improve efficacy but boost it.
About time started Boosting
KEY POINTS
A patient selection strategy is essential to rapid drug approval.
Expansion phases of phase I trials allow early establishment of disease response rates.
Biomarkers for patient selection can be validated in expanded phase I.
One confirmatory phase II may be sufficient for accelerated approval.
Postapproval trials may refine the dose, schedule, sequence, and combination therapies.
https://ascopubs.org/doi/10.14694/EdBook_AM.2012.32.114
Update on AVA6000 Phase 1a Clinical Trial Progress.
Presenter/Authors
U. Banerji, N. Cook, A. Anthoney, R. Plummer, W. D. Tap, J. T. R. Evans, L. D. Cranmer, C. Plummer, P. Loadman, G. Lahu, H. S. Jones, N. Kinnersley, F. McLaughlin, C.
Or Trolls
This is a statement from 2018
On the collaboration with Tufts talking about TMac, could they be ready to partner at an early stage for TMac knowing how well Pre/Cision works now.
“We believe that this new drug conjugate platform is transformational for the business. From our initial discussions with several large pharmaceutical companies, it is clear that there is significant interest and there is certainly the potential for partnering at an early stage once we have the appropriate supporting data from the collaboration with Professor Bachovchin.”
https://www.labmate-online.com/news/news-and-views/5/avacta-group/collaboration-to-develop-novel-class-of-drug-conjugate/46762
Courtesy of gggg21 on X
AVA7000 & AVA7500
https://synapse.patsnap.com/target/34d84f7e2cdd39e98653d20cf3a9d84e
https://www.ipo.gov.uk/p-pj/p-pj-ukappfiled?startYear=2023&startMonth=March&startDay=29th+-+6984&endYear=2024&endMonth=March&endDay=27th+-+7036&filter=avacta&perPage=50&sort=Publication+Date
That was wynbore
Markets don’t see it that way.
They are reacting like they need change .
Everyone believes in the science but if you have an incompetent CEO you need to change.
What are you worried about your just a paid troll
Sad 🤡
Please explain why you trashed the SP
for II money that is not coming in.
We need answers for your incompetence over the last month.
Leave Gardiner playing with his abacus and start taking responsibility for your actions.
You need to calm the markets and show them some commercialisation soon.